84 related articles for article (PubMed ID: 12700464)
21. Impact of P-glycoprotein on clopidogrel absorption.
Taubert D; von Beckerath N; Grimberg G; Lazar A; Jung N; Goeser T; Kastrati A; Schömig A; Schömig E
Clin Pharmacol Ther; 2006 Nov; 80(5):486-501. PubMed ID: 17112805
[TBL] [Abstract][Full Text] [Related]
22. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Hampson L; Kitchener HC; Hampson IN
Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
[TBL] [Abstract][Full Text] [Related]
23. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein.
Griffin J; Fletcher N; Clemence R; Blanchflower S; Brayden DJ
J Vet Pharmacol Ther; 2005 Jun; 28(3):257-65. PubMed ID: 15953199
[TBL] [Abstract][Full Text] [Related]
24. Stereoselective regulation of MDR1 expression in Caco-2 cells by cetirizine enantiomers.
Shen S; He Y; Zeng S
Chirality; 2007 Jun; 19(6):485-90. PubMed ID: 17394131
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
[TBL] [Abstract][Full Text] [Related]
26. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
Marcelin AG; Cohen-Codar I; King MS; Colson P; Guillevic E; Descamps D; Lamotte C; Schneider V; Ritter J; Segondy M; Peigue-Lafeuille H; Morand-Joubert L; Schmuck A; Ruffault A; Palmer P; Chaix ML; Mackiewicz V; Brodard V; Izopet J; Cottalorda J; Kohli E; Chauvin JP; Kempf DJ; Peytavin G; Calvez V
Antimicrob Agents Chemother; 2005 May; 49(5):1720-6. PubMed ID: 15855487
[TBL] [Abstract][Full Text] [Related]
27. Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways.
Hou XL; Takahashi K; Tanaka K; Tougou K; Qiu F; Komatsu K; Takahashi K; Azuma J
Int J Pharm; 2008 Jun; 358(1-2):224-9. PubMed ID: 18439772
[TBL] [Abstract][Full Text] [Related]
28. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
[TBL] [Abstract][Full Text] [Related]
29. Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.
Prot M; Heripret L; Cardot-Leccia N; Perrin C; Aouadi M; Lavrut T; Garraffo R; Dellamonica P; Durant J; Le Marchand-Brustel Y; Binétruy B
Antimicrob Agents Chemother; 2006 Dec; 50(12):3998-4004. PubMed ID: 17000748
[TBL] [Abstract][Full Text] [Related]
30. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
[TBL] [Abstract][Full Text] [Related]
31. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide does not interact with P-glycoprotein.
Zimmermann C; Gutmann H; Drewe J
Cancer Chemother Pharmacol; 2006 May; 57(5):599-606. PubMed ID: 16136308
[TBL] [Abstract][Full Text] [Related]
33. Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.
Flosi WJ; DeGoey DA; Grampovnik DJ; Chen HJ; Klein LL; Dekhtyar T; Masse S; Marsh KC; Mo HM; Kempf D
Bioorg Med Chem; 2006 Oct; 14(19):6695-712. PubMed ID: 16828558
[TBL] [Abstract][Full Text] [Related]
34. Effects of continuous exposure to digoxin on MDR1 function and expression in Caco-2 cells.
Takara K; Tsujimoto M; Ohnishi N; Yokoyama T
J Pharm Pharmacol; 2003 May; 55(5):675-81. PubMed ID: 12831511
[TBL] [Abstract][Full Text] [Related]
35. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells.
Yoo HH; Lee M; Chung HJ; Lee SK; Kim DH
J Agric Food Chem; 2007 Sep; 55(18):7620-5. PubMed ID: 17676865
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).
Sham HL; Betebenner DA; Herrin T; Kumar G; Saldivar A; Vasavanonda S; Molla A; Kempf DJ; Plattner JJ; Norbeck DW
Bioorg Med Chem Lett; 2001 Jun; 11(11):1351-3. PubMed ID: 11378352
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of MRP-like activity in human erythrocytes: inhibitory effect of isoflavones.
Bobrowska-Hägerstrand M; Wróbel A; Rychlik B; Bartosz G; Söderström T; Shirataki Y; Motohashi N; Molnár J; Michalak K; Hägerstrand H
Blood Cells Mol Dis; 2001; 27(5):894-900. PubMed ID: 11783953
[TBL] [Abstract][Full Text] [Related]
38. Detection of P-glycoprotein efflux activity on peripheral blood lymphocyte subsets from HIV+ patients.
Lucia MB; Rutella S; Rumi C; Ventura G; Caldarola G; Cauda R
Eur J Histochem; 1997; 41 Suppl 2():195-6. PubMed ID: 9859845
[No Abstract] [Full Text] [Related]
39. Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir).
Sham HL; Betebenner DA; Chen X; Saldivar A; Vasavanonda S; Kempf DJ; Plattner JJ; Norbeck DW
Bioorg Med Chem Lett; 2002 Apr; 12(8):1185-7. PubMed ID: 11934584
[TBL] [Abstract][Full Text] [Related]
40. Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships.
Sham HL; Zhao C; Li L; Betebenner DA; Saldivar A; Vasavanonda S; Kempf DJ; Plattner JJ; Norbeck DW
Bioorg Med Chem Lett; 2002 Nov; 12(21):3101-3. PubMed ID: 12372511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
